Core Insights - Citius Pharmaceuticals and Citius Oncology will participate in three investor conferences in October 2025, providing opportunities for one-on-one meetings with management [1][2][3]. Company Overview - Citius Pharmaceuticals, Inc. is focused on developing first-in-class critical care products, with FDA approval for LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, received in August 2024 [4]. - Citius Pharmaceuticals' late-stage pipeline includes Mino-Lok, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, with successful trial completions in 2023 [4]. - Citius Pharmaceuticals owns 79% of Citius Oncology, which specializes in novel targeted oncology therapies [4][5]. Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [5]. - Citius Oncology has robust intellectual property protections, including orphan drug designation and pending patents, which enhance its competitive positioning in the oncology market [5][6].